Huasen Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 62.98 million yuan, an increase of 9.03 million yuan compared with the same period last year, up 16.74% year-on-year, achieving three consecutive years of growth. The company's total operating revenue was 414 million yuan, a decrease of 28.36 million yuan from the same period last year, down 6.42% year-on-year. Net cash inflow from operating activities was 54.66 million yuan, up 98.58% year-on-year. The company's latest asset-liability ratio was 14.77%, gross margin was 59.26%, ROE was 3.62%, and diluted earnings per share was 0.15 yuan.
Chongqing Pharscin Pharmaceutical Co LtdNet profit up 16.74% year-on-year, marking three consecutive years of growth.
